{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:31:20Z","timestamp":1789133480147,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.dld.2024.10.012","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:43:02Z","timestamp":1730274182000},"page":"558-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Why and when could nucleos(t)ide analogues treatment be withdrawn?"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-1598","authenticated-orcid":false,"given":"Jimmy Che-To","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Colombatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia Rossana","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2024.10.012_bib0001","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.10.012_bib0002","unstructured":"World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Published on 29 March 2024. Website: https:\/\/www.who.int\/publications\/i\/item\/9789240090903. Accessed on 23 May 2024."},{"key":"10.1016\/j.dld.2024.10.012_bib0003","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0004","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3350\/cmh.2018.0106","article-title":"Unmet need in chronic hepatitis B management","volume":"25","author":"Liang","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0005","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.10.012_bib0006","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis","volume":"50","author":"Liu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.10.012_bib0007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0008","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2022.11.020","article-title":"Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss","volume":"78","author":"Yip","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0009","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0010","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/apt.14497","article-title":"Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B","volume":"47","author":"Wong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.10.012_bib0011","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jhep.2023.12.001","article-title":"Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B","volume":"80","author":"Yip","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0012","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","article-title":"Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety","volume":"119","author":"Chan","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2024.10.012_bib0013","first-page":"165","article-title":"Lactic Acidosis during Entecavir Antiviral Treatment in a Patient with Hepatitis B Virus-related Decompensated Cirrhosis","volume":"64","author":"Mao","year":"2015","journal-title":"West Indian Med J"},{"key":"10.1016\/j.dld.2024.10.012_bib0014","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","article-title":"Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir","volume":"113","author":"Shin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2024.10.012_bib0015","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2024.10.012_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2024.10.012_bib0017","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2024.10.012_bib0018","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.10.012_bib0019","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.10.012_bib0020","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2024.10.012_bib0021","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0022","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.10.012_bib0023","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dld.2024.10.012_bib0024","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B","volume":"41","author":"Chi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.10.012_bib0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0026","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hep.29821","article-title":"Less can be more: a finite treatment approach for HBeAg-negative chronic hepatitis B","volume":"68","author":"Lampertico","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.10.012_bib0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.10.012_bib0028","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0029","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van Bommel","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: an International, Multicenter, Multiethnic Cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.10.012_bib0031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to Chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.10.012_bib0032","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: a systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2024.10.012_bib0033","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.10.012_bib0034","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2024.10.012_bib0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/135965350601100201","article-title":"A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy","volume":"11","author":"Colombatto","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2024.10.012_bib0036","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coisb.2019.10.003","article-title":"Within-host mathematical models of hepatitis B virus infection: past, present, and future","volume":"18","author":"Goyal","year":"2019","journal-title":"Curr Opin Syst Biol"},{"key":"10.1016\/j.dld.2024.10.012_bib0037","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.10.012_bib0038","article-title":"Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells","volume":"4","author":"Tu","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2024.10.012_bib0039","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.10.012_bib0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0041","article-title":"Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed","volume":"2","author":"Lai","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2024.10.012_bib0042","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.10.012_bib0043","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/gutjnl-2023-330577","article-title":"Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss","volume":"73","author":"Yu","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.10.012_bib0044","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/liv.15140","article-title":"Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies","volume":"42","author":"Liu","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2024.10.012_bib0045","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17474124.2022.2156338","article-title":"Hepatitis B flare: the good, the bad and the ugly","volume":"16","author":"Liaw","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0046","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV 'cure","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0047","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/jvh.13742","article-title":"Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B","volume":"29","author":"Liem","year":"2022","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2024.10.012_bib0048","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0049","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.10.012_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011238","article-title":"Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers","volume":"20","author":"Kitagawa","year":"2024","journal-title":"PLoS Comput Biol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824010570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824010570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:49:09Z","timestamp":1741178949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824010570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1590865824010570"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.10.012","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why and when could nucleos(t)ide analogues treatment be withdrawn?","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}